enVVeno Medical Corporation (NASDAQ:NVNO – Get Free Report) saw a significant growth in short interest in the month of October. As of October 30th, there was short interest totaling 24,103 shares, a growth of 104.8% from the October 15th total of 11,771 shares. Based on an average daily trading volume, of 39,897 shares, the short-interest ratio is presently 0.6 days. Approximately 4.1% of the company’s stock are short sold.
enVVeno Medical Price Performance
NVNO traded down $0.29 during trading hours on Monday, reaching $5.88. 10,422 shares of the stock traded hands, compared to its average volume of 20,933. enVVeno Medical has a fifty-two week low of $5.80 and a fifty-two week high of $14.66. The company has a market cap of $4.05 million, a price-to-earnings ratio of -0.35 and a beta of 1.41. The firm’s fifty day simple moving average is $8.11 and its two-hundred day simple moving average is $10.09.
enVVeno Medical (NASDAQ:NVNO – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported ($6.29) EPS for the quarter, missing analysts’ consensus estimates of ($3.27) by ($3.02). On average, research analysts predict that enVVeno Medical will post -16.19 earnings per share for the current year.
Analyst Ratings Changes
NVNO has been the topic of several analyst reports. Wall Street Zen downgraded enVVeno Medical from a “hold” rating to a “sell” rating in a report on Sunday, November 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of enVVeno Medical in a research report on Friday, September 25th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, enVVeno Medical currently has an average rating of “Hold”.
Get Our Latest Stock Report on NVNO
About enVVeno Medical
enVVeno Medical is a medical-device company developing treatments for chronic venous disease, with a focus on deep venous chronic venous insufficiency. This condition can occur when valves in the leg’s deep veins do not function properly, impairing blood flow back to the heart. The company’s lead product, VenoValve, is a bioprosthetic valve designed to restore valve function in affected deep veins. enVVeno has also described a transcatheter valve program, enVVe, intended to provide a less invasive approach to treating the condition.
Further Reading
- Five stocks we like better than enVVeno Medical
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for enVVeno Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enVVeno Medical and related companies with MarketBeat.com's FREE daily email newsletter.
